AMEERA-3 is an open-label randomized phase II study of amcenestrant (SAR439859) versus treatment of physician’s choice (fulvestrant/aromatase inhibitors/estrogen receptor modular) in locally advanced or metastatic ER + breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.